Federal Rescheduling of Medical Marijuana: What It Means for States and Businesses
The U.S. Department of Justice’s decision in April to move medical cannabis from Schedule I to Schedule III has been hailed as a acknowledgment of the plant’s accepted medical use. While the change opens the door to certain federal tax benefits and research opportunities, it also leaves a patchwork of state regulations facing new questions about compliance, licensing, and future guidance.
Recreational marijuana, however, remains classified as a Schedule I substance under federal law, even though 24 states and the District of Columbia now permit adult‑use cannabis in various forms. This split creates a dual‑track system where the same plant is treated differently depending on its intended use.
Background on the Rescheduling Decision
The rescheduling follows a long‑standing push from medical advocates and industry groups to ease the federal barriers that have hampered cannabis businesses for decades. Under Schedule III, medical cannabis is considered to have a moderate to low potential for dependence and accepted medical use, which allows physicians to prescribe it more readily and enables researchers to work with fewer bureaucratic hurdles.
Katharine Neill Harris, a drug policy fellow at Rice University’s Baker Institute for Public Policy, noted that the move “is sort of catching up to what states are already doing” and that “in some ways the federal government is following the states on this issue.”
State‑Level Reactions and Uncertainty
State cannabis regulators have largely greeted the news with cautious optimism, stressing that existing state laws remain unchanged until federal agencies issue concrete rules. In Nevada, officials pointed out that the rescheduling lets medical cannabis licensees register with the Drug Enforcement Administration (DEA) while reiterating that state law still treats non‑medical marijuana as a Schedule I drug.
In California, the Department of Cannabis Control proposed emergency regulations in mid‑May that would allow businesses holding both medical and recreational licenses to obtain separate permits, positioning them to capitalize on any federal benefits tied to the medical‑cannabis shift.
Yet many state officials say they are waiting for further direction before advising licensees. James Pepper, chair of the Vermont Cannabis Control Board, captured the sentiment: “None of us really can effectively advise our licensees, which is just incredibly frustrating, especially with a ticking clock.” Similar waits are reported in Oklahoma, Vermont, and Washington, where regulators are holding off on decisions about DEA registration, tax relief, or potential law revisions until federal guidance arrives.
Potential Benefits: Taxation and Research
One of the most immediate impacts of the Schedule III designation is the possibility for cannabis businesses to claim federal tax deductions that were previously barred under Section 280E of the Internal Revenue Code. Lauren Niehaus, executive director of government relations at Trulieve Cannabis Corp., explained that “going forward, we can be treated and taxed like a normal business, which ultimately helps the bottom line and allows us to reinvest more meaningfully in the states where we operate.”
Beyond taxation, researchers anticipate that the lower schedule will reduce barriers to studying cannabis’s medical efficacy, safety, and long‑term health effects. Chad Johnson, assistant professor of pharmaceutical sciences at the University of Maryland School of Pharmacy, emphasized the need for randomized trials to confirm therapeutic benefits and pointed out that rescheduling could let academic institutions study products already sold in state dispensaries, aligning research more closely with real‑world consumer use.
Ongoing Challenges and Legal Risks
Despite the optimism, significant uncertainties persist. The DEA’s planned hearing at the end of June on the possible de‑scheduling of marijuana broadly could reshape the landscape again, but until then, businesses face a confusing regulatory environment. Some states, such as Oklahoma, have already urged licensees to register with the DEA, warning of possible sanctions for non‑compliance, while other state agencies question whether such federal registration will actually be required.
Financial institutions remain hesitant to serve cannabis firms because marijuana’s federal illegality exposes banks to regulatory risk. Although several congressional bills aim to provide safe‑harbor protections for banks working with cannabis businesses, none have become law, leaving the industry largely cash‑dependent.
Legal challenges have also emerged. Attorneys general from Indiana, Louisiana, and Nebraska filed a petition arguing that the Justice Department’s rescheduling order violates federal administrative law, while groups like Smart Approaches to Marijuana contend the administration overstepped its authority under the Controlled Substances Act.
Looking Ahead
As the June DEA hearing approaches, state officials, industry leaders, and researchers are watching closely for any federal guidance that could clarify tax treatment, registration requirements, and research permissions. The outcome will likely shape how quickly cannabis businesses can transition from operating in a legal gray zone to functioning more like traditional enterprises, while also influencing the pace and direction of scientific inquiry into cannabis’s therapeutic potential.
For now, the cannabis landscape remains a blend of promise and patience—states continue to refine their own frameworks, businesses weigh the advantages of federal recognition against lingering compliance risks, and advocates await a clearer national policy that matches the evolving reality on the ground.
Source: Here
⚖️ The U.S. Department of Justice recently reclassified medical marijuana from Schedule I to Schedule III, raising many questions as states across the nation wait in anticipation of the June DEA hearing.
“[…] the broader divide between federal and state marijuana policy… pic.twitter.com/uARoq5wkdC
— Oklahoma Medical Marijuana Authority (@OMMAOK) May 29, 2026
